Press Releases

Press Releases

Schrödinger Presents Data from Its MALT1 Inhibitor Program at the American Society of Hematology (ASH) 2020 Annual Meeting

NEW YORK --(BUSINESS WIRE)--Dec. 7, 2020-- Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, presented preclinical data from its wholly-owned MALT1 inhibitor program in B-cell lymphomas at the virtual 62 nd  
December 7, 2020

Schrödinger Announces a Multi-Target Drug Discovery, Development, and Commercialization Collaboration with Bristol Myers Squibb

Schrödinger to receive $55 million upfront; eligible to receive up to $2.7 billion in milestone payments plus royalties NEW YORK --(BUSINESS WIRE)--Nov. 23, 2020-- Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based software platform is transforming the way therapeutics and materials are
November 23, 2020

Schrödinger, Inc. Reports Third Quarter 2020 Financial Results and Business Update

Total revenue of $25.8 million , up 29% year-over-year; Software revenue of $22.9 million , up 42% year-over-year Raised $325.6 million net proceeds in equity financing Presenting data on our MALT 1 inhibitor program at the American Society of Hematology (ASH) Annual Meeting & Exposition Conference
November 12, 2020

Schrödinger to Present at Upcoming Investor Conferences

NEW YORK --(BUSINESS WIRE)--Nov. 10, 2020-- Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, today announced that members of the management team will participate in the upcoming virtual investor conferences in
November 10, 2020

Schrödinger to Present Data from Its MALT1 Inhibitor Program at the American Society of Hematology (ASH) 2020 Annual Meeting

NEW YORK --(BUSINESS WIRE)--Nov. 5, 2020-- Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, today announced it will present data from its preclinical MALT1 inhibitor program at the 62nd American Society of
November 5, 2020

Schrödinger to Host Third Quarter 2020 Financial Results Conference Call and Webcast

NEW YORK --(BUSINESS WIRE)--Nov. 5, 2020-- Schrödinger (Nasdaq: SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, today announced it will host a conference call and webcast on Thursday, November 12, 2020 at 8:30 a.m.
November 5, 2020

Schrödinger to Present at the Morgan Stanley 18th Annual Global Healthcare Conference

NEW YORK --(BUSINESS WIRE)--Sep. 8, 2020-- Schrödinger (Nasdaq: SDGR), whose physics-based software platform enables discovery of high-quality, novel molecules for therapeutics and materials, today announced that members of the management team will participate in a fireside chat at the Morgan
September 8, 2020

Schrödinger Announces Closing of Public Offering

NEW YORK --(BUSINESS WIRE)--Aug. 17, 2020-- Schrödinger, Inc. (the “Company”) (Nasdaq: SDGR), whose differentiated, physics-based software platform enables discovery of high-quality, novel molecules for drug development and materials applications, today announced the closing of its underwritten
August 17, 2020

Schrödinger Announces Pricing of Public Offering

NEW YORK --(BUSINESS WIRE)--Aug. 12, 2020-- Schrödinger, Inc. (the “Company”) (Nasdaq: SDGR), whose differentiated, physics-based software platform enables discovery of high-quality, novel molecules for drug development and materials applications, today announced the pricing of an underwritten
August 12, 2020

Schrödinger Announces Proposed Public Offering of Common Stock

NEW YORK --(BUSINESS WIRE)--Aug. 10, 2020-- Schrödinger, Inc. (Nasdaq: SDGR), whose differentiated, physics-based software platform enables discovery of high-quality, novel molecules for drug development and materials applications, today announced the commencement of a proposed underwritten public
August 10, 2020
Displaying 1 - 10 of 25
Back To Top